Impact of GxAlert on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papua New Guinea

J. K. Banamu, Evelyn Lavu, K. Johnson, R. Moke, S Majumdar, K. C. Takarinda, Robert Commons

    Research output: Contribution to journalArticle

    Abstract

    Setting: GxAlert is an automatic electronic notification service that provides immediate Xpert® MTB/RIF testing results. It was implemented for the notification of patients with rifampicin resistant-tuberculosis (RR-TB) atPort Moresby General Hospital, Port Moresby, Papua New Guinea, in May 2015.

    Objective: To determine if there were differences in pre-treatment attrition, the time to treatment initiation and patient outcomes in the 12 months pre- and post-introduction of GxAlert for RR-TB patients.

    Design: This was a retrospective cohort study.

    Results: The median time from Xpert testing to treatment initiation decreased from 35 days [IQR 13–131] prior to GxAlert to 10 days [IQR 3–29] after GxAlert (P =0.001), with the cumulative proportion of patients initiating treatment within 30 days increasing from 25% (95%CI 17–37) to 54% (95%CI 44–64; P < 0.001) over these periods. However, our analysis of the time to treatment prior to the introduction of GxAlert suggests that a decrease had already occurred prior to implementation. There was no difference in interim clinical outcomes between the periods.

    Conclusion: Although a decrease in time to treatment initiation cannot be attributed to GxAlert, there was a significant improvement over the 2-year period, suggesting that considerable improvements have been made intimely RR-TB patient management in Port Moresby
    Original languageEnglish
    Pages (from-to)S19-S24
    Number of pages6
    JournalPublic Health Action
    Volume9
    Issue numberSupplement 1
    DOIs
    Publication statusPublished - 21 Sep 2019

    Fingerprint Dive into the research topics of 'Impact of GxAlert on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papua New Guinea'. Together they form a unique fingerprint.

  • Cite this

    Banamu, J. K., Lavu, E., Johnson, K., Moke, R., Majumdar, S., Takarinda, K. C., & Commons, R. (2019). Impact of GxAlert on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papua New Guinea. Public Health Action, 9(Supplement 1), S19-S24. https://doi.org/10.5588/pha.18.0067